JP6978122B2 - 自閉症および関連障害の治療および予防のための腸管選択的隔離剤 - Google Patents

自閉症および関連障害の治療および予防のための腸管選択的隔離剤 Download PDF

Info

Publication number
JP6978122B2
JP6978122B2 JP2020502532A JP2020502532A JP6978122B2 JP 6978122 B2 JP6978122 B2 JP 6978122B2 JP 2020502532 A JP2020502532 A JP 2020502532A JP 2020502532 A JP2020502532 A JP 2020502532A JP 6978122 B2 JP6978122 B2 JP 6978122B2
Authority
JP
Japan
Prior art keywords
mice
intestinal
metabolites
sequestering
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2020502532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513032A5 (enExample
JP2020513032A (ja
Inventor
キャンベル，アンソニー，スチュワート
ドナベディアン，デヴィッド，エイチ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axial Therapeutics Inc
Original Assignee
Axial Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axial Biotherapeutics Inc filed Critical Axial Biotherapeutics Inc
Publication of JP2020513032A publication Critical patent/JP2020513032A/ja
Publication of JP2020513032A5 publication Critical patent/JP2020513032A5/ja
Application granted granted Critical
Publication of JP6978122B2 publication Critical patent/JP6978122B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020502532A 2017-03-31 2018-03-31 自閉症および関連障害の治療および予防のための腸管選択的隔離剤 Expired - Fee Related JP6978122B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480039P 2017-03-31 2017-03-31
US62/480,039 2017-03-31
PCT/US2018/025607 WO2018183986A1 (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Publications (3)

Publication Number Publication Date
JP2020513032A JP2020513032A (ja) 2020-04-30
JP2020513032A5 JP2020513032A5 (enExample) 2021-04-15
JP6978122B2 true JP6978122B2 (ja) 2021-12-08

Family

ID=63677186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502532A Expired - Fee Related JP6978122B2 (ja) 2017-03-31 2018-03-31 自閉症および関連障害の治療および予防のための腸管選択的隔離剤

Country Status (9)

Country Link
US (4) US10617718B2 (enExample)
EP (1) EP3600349A4 (enExample)
JP (1) JP6978122B2 (enExample)
KR (1) KR102328323B1 (enExample)
CN (2) CN110944650B (enExample)
AU (3) AU2018243836B9 (enExample)
BR (1) BR112019020289A2 (enExample)
CA (2) CA3191747A1 (enExample)
WO (1) WO2018183986A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2021011481A1 (en) * 2019-07-12 2021-01-21 The General Hospital Corporation Anti-inflammatory factors
JP7607659B2 (ja) * 2019-12-19 2024-12-27 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド トマトの搾りかすを用いたイヌの上昇した４－エチルフェニル硫酸と関連付けられた状態の治療およびリスクを低減する組成物および方法ならびにそのような状態のリスクにあるイヌを特定する方法
US20240197795A1 (en) * 2020-07-27 2024-06-20 Boadie DUNLOP Assessment and treatment of depression, anxiety, or related disorders
CN113440522B (zh) * 2021-07-29 2022-12-13 中山大学附属第七医院(深圳) 一种吲哚丙酸在制备用于治疗自闭症药物中的应用
CN115825314A (zh) * 2021-09-17 2023-03-21 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物s-甲基-5′-硫代腺苷及其应用
WO2023154966A1 (en) * 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Compositions and methods for sequestering metabolites in the gastrointestinal tract
WO2023154547A1 (en) 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Colon targeted drug delivery
CN116990395A (zh) * 2022-04-26 2023-11-03 中国科学院深圳先进技术研究院 一种基于粪便的阿尔兹海默症生物标志物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
JPS5673542A (en) * 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
GB9611437D0 (en) 1995-08-03 1996-08-07 Secr Defence Biomaterial
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
JP2008523100A (ja) * 2004-12-13 2008-07-03 アリーナ ファーマシューティカルズ， インコーポレイテッド ５ｈｔ２ｃ受容体に関連した疾患の治療に有用な５ｈｔ２ｃ受容体のモジュレータとしてのｎ−ビアリール及びｎ−アリールヘテロアリール２−置換ピペラジン誘導体
WO2010102218A1 (en) * 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
KR101593287B1 (ko) * 2011-03-04 2016-02-11 가부시끼가이샤 구레하 정제형의 경구 투여용 조성물 및 그의 제조 방법
US20140213534A1 (en) * 2011-05-23 2014-07-31 Thomas Jefferson University Intestinal hyperpermeability and prevention of systemic disease
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
CN114949001A (zh) * 2012-08-29 2022-08-30 加州理工学院 孤独症谱系障碍的诊断和治疗
TWI520751B (zh) 2013-02-22 2016-02-11 吳羽股份有限公司 經口投予用吸附劑及腎疾病治療劑及肝疾病治療劑
MX2016000293A (es) 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
KR20160034352A (ko) * 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
US9763903B2 (en) * 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
WO2015150590A1 (en) * 2014-04-04 2015-10-08 Biotechnobel Sa Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제

Also Published As

Publication number Publication date
CN114569633A (zh) 2022-06-03
US11007219B2 (en) 2021-05-18
NZ758692A (en) 2022-03-25
BR112019020289A2 (pt) 2020-09-01
AU2018243836B2 (en) 2021-04-22
EP3600349A4 (en) 2020-09-30
CA3095724A1 (en) 2018-10-04
AU2021206871B2 (en) 2021-10-14
CA3191747A1 (en) 2018-10-04
AU2018243836B9 (en) 2021-05-13
AU2022200220A1 (en) 2022-02-10
US20230364135A1 (en) 2023-11-16
US20180303876A1 (en) 2018-10-25
CN110944650B (zh) 2022-03-04
KR102328323B1 (ko) 2021-11-19
JP2020513032A (ja) 2020-04-30
KR20200024133A (ko) 2020-03-06
AU2021206871A1 (en) 2021-08-12
CA3095724C (en) 2023-04-18
WO2018183986A1 (en) 2018-10-04
CN110944650A (zh) 2020-03-31
AU2018243836A1 (en) 2019-11-21
US10617718B2 (en) 2020-04-14
CN114569633B (zh) 2023-11-17
EP3600349A1 (en) 2020-02-05
US20200368276A1 (en) 2020-11-26
US20200390809A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
US20230364135A1 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
ES2859758T3 (es) Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intestinal
TW201919668A (zh) 包含細菌品系之組成物
JP2019523758A (ja) 神経変性障害を治療するための腸内微生物叢の制御
US11123379B2 (en) Compositions comprising bacterial strains
JP2018111699A (ja) 肝疾患の治療及び予防における使用のための多孔性炭素粒子
Hu et al. Encapsulated lactiplantibacillus plantarum improves Alzheimer’s symptoms in APP/PS1 mice
EP3979830A1 (en) Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
TW202116333A (zh) 包含細菌品系之組成物
CN115003318A (zh) 包含细菌菌株的组合物
HK40075263A (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
NZ785988A (en) Gut-selective sequestering agents for the treatment and prevention of autism and
Mishra et al. Gut-Brain Axis: Understanding the Interlink Between Alterations in the Gut Microbiota and Autism Spectrum Disorder
NZ758692B2 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
WO2023154966A1 (en) Compositions and methods for sequestering metabolites in the gastrointestinal tract
JP2006176450A (ja) 小腸でのリンの過剰吸収を抑制可能とする乳酸菌含有組成物
KR20210021085A (ko) 박테리아 균주를 포함하는 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210302

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210302

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210903

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211104

R150 Certificate of patent or registration of utility model

Ref document number: 6978122

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees